Form 4: Orchestra BioMed CFO Andrew Taylor Receives 84,000 Restricted Stock Units

Andrew Lawrence Taylor, CFO of Orchestra BioMed Holdings, Inc., was granted 84,000 restricted stock units on April 4, 2025, according to a Form 4 filing with the SEC.

Summary

• Andrew Lawrence Taylor, the Chief Financial Officer of Orchestra BioMed Holdings, Inc., received 84,000 restricted stock units (RSUs) on April 4, 2025.
• These RSUs represent a contingent right to receive one share of common stock per unit.
• The RSUs vest over a three-year period: 33.33% vest 24 months after the issue date (April 4, 2025), 33.33% vest 30 months after, and 33.34% vest 36 months after, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the company's future, but it also represents potential dilution for existing shareholders.

Positives

• The grant of RSUs aligns the CFO's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Risks

• The value of the RSUs is dependent on the future stock price of Orchestra BioMed Holdings, Inc., which is subject to market risks.
• If the CFO's employment terminates before the vesting dates, the unvested RSUs will be forfeited.

Future Outlook

The vesting schedule implies a focus on long-term value creation and retention of key personnel.

Industry Context

Granting RSUs to executives is a common practice in the biotech industry to incentivize performance and align management's interests with shareholders.

Stakeholder Impact

• Shareholders may experience slight dilution due to the issuance of new shares upon RSU vesting.
• Employees may view the RSU grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

restricted stock units, RSUs, Orchestra BioMed, Andrew Taylor, CFO, Form 4, beneficial ownership, equity compensation, vesting